![GDNF/GFRα1 treatment stimulates growth of transplantable HSCs. (A) Experimental design for GDNF/GFRα1–supplemented outgrowth of HSCs and transplantation ability. 1°TP and 2°TP represent the first and second transplantation, respectively. (B) Live cell count of in vitro cultured HSPCs (N = 5). Proportion of expanded HSCs (CD34+CD90+EPCR+) at day 3 (C) and day 7 (D) during in vitro culture (N = 5). (E) Percentage of human CD45+ (hCD45+) cells of total CD45+ bone marrow cells in primary transplantation mice (control [Ctrl], N = 12; GDNF/GFRα1, N = 10; SR1/UM171, N = 7; SR1/UM171/GDNF/GFRα1, N = 6). (F) Percentage of immunophenotypic HSCs (CD34+CD38–CD45RA–CD90+CD49f+) retained in hCD45 bone marrow cells in primary transplantation mice. (G) Percentage of hCD45+ cells of total CD45+ bone marrow cells in secondary transplantation mice (2 × 105 hCD45 cells transplanted shown, N = 5 for all conditions). (H) Boxplot indicating 1/stem cell frequency of secondary transplanted hCD45+ cells. Estimates with upper and lower intervals are shown (N = 5 for top dose, N = 3 for all other doses). For all graphs, a Student t test was used to calculated significant differences. *P < .05 vs Ctrl; **P < .005 vs Ctrl; ***P < .0005 vs Ctrl; ****P < .00005 vs Ctrl.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/136/22/10.1182_blood.2020006302/1/bloodbld2020006302f2.png?Expires=1721692155&Signature=D8Vis0Q6e29T6n~UnV6pdaptSp5g8kQ6SVQxvCgJL5QIDVmMK1OYA~czvfSvEuBfn3Z9Pl-3H-GfQgu8fdkjPwA~PIa7iRcCZM7xlKWQM2nPe-kvFMNA-P3orH6ublpG59X8rqmBqwGz98iPdKEYHQScGI60XEGvLiXDavQkqk-KPheEJYM4HK8GR~WDIPvMabyV7KGUsfRt11RUsxaeMANYri6ted7iTyvOROfLMACoBnzmgf5LgzjN~ySbXJghAdjazFpu9rA~~WAUzav8zX5N9EZrWUwuTuKD2Cz-oJjTzYtLI1jwfYUDay1qHtkquDE5qwJ5h07~0vMe7RnTgg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
GDNF/GFRα1 treatment stimulates growth of transplantable HSCs. (A) Experimental design for GDNF/GFRα1–supplemented outgrowth of HSCs and transplantation ability. 1°TP and 2°TP represent the first and second transplantation, respectively. (B) Live cell count of in vitro cultured HSPCs (N = 5). Proportion of expanded HSCs (CD34+CD90+EPCR+) at day 3 (C) and day 7 (D) during in vitro culture (N = 5). (E) Percentage of human CD45+ (hCD45+) cells of total CD45+ bone marrow cells in primary transplantation mice (control [Ctrl], N = 12; GDNF/GFRα1, N = 10; SR1/UM171, N = 7; SR1/UM171/GDNF/GFRα1, N = 6). (F) Percentage of immunophenotypic HSCs (CD34+CD38–CD45RA–CD90+CD49f+) retained in hCD45 bone marrow cells in primary transplantation mice. (G) Percentage of hCD45+ cells of total CD45+ bone marrow cells in secondary transplantation mice (2 × 105 hCD45 cells transplanted shown, N = 5 for all conditions). (H) Boxplot indicating 1/stem cell frequency of secondary transplanted hCD45+ cells. Estimates with upper and lower intervals are shown (N = 5 for top dose, N = 3 for all other doses). For all graphs, a Student t test was used to calculated significant differences. *P < .05 vs Ctrl; **P < .005 vs Ctrl; ***P < .0005 vs Ctrl; ****P < .00005 vs Ctrl.